- Home
- ASLE vs ATXS Comparison
ASLE vs ATXS Comparison
Compare ASLE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASLE
- ATXS
- Stock Information
- Founded
- ASLE 2008
- ATXS 2008
- Country
- ASLE United States
- ATXS United States
- Employees
- ASLE N/A
- ATXS N/A
- Industry
- ASLE Industrial Specialties
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ASLE Consumer Discretionary
- ATXS Health Care
- Exchange
- ASLE Nasdaq
- ATXS Nasdaq
- Market Cap
- ASLE 363.4M
- ATXS 401.2M
- IPO Year
- ASLE N/A
- ATXS 2015
- Fundamental
- Price
- ASLE $7.70
- ATXS $5.40
- Analyst Decision
- ASLE Strong Buy
- ATXS Strong Buy
- Analyst Count
- ASLE 3
- ATXS 5
- Target Price
- ASLE $9.00
- ATXS $26.60
- AVG Volume (30 Days)
- ASLE 835.7K
- ATXS 285.8K
- Earning Date
- ASLE 03-06-2025
- ATXS 03-11-2025
- Dividend Yield
- ASLE N/A
- ATXS N/A
- EPS Growth
- ASLE N/A
- ATXS N/A
- EPS
- ASLE 0.11
- ATXS N/A
- Revenue
- ASLE $345,066,000.00
- ATXS N/A
- Revenue This Year
- ASLE $20.10
- ATXS N/A
- Revenue Next Year
- ASLE $20.35
- ATXS N/A
- P/E Ratio
- ASLE $68.09
- ATXS N/A
- Revenue Growth
- ASLE 3.16
- ATXS N/A
- 52 Week Low
- ASLE $4.53
- ATXS $5.24
- 52 Week High
- ASLE $9.40
- ATXS $13.33
- Technical
- Relative Strength Index (RSI)
- ASLE 48.23
- ATXS 30.54
- Support Level
- ASLE $8.07
- ATXS $5.89
- Resistance Level
- ASLE $8.56
- ATXS $6.52
- Average True Range (ATR)
- ASLE 0.34
- ATXS 0.37
- MACD
- ASLE -0.11
- ATXS -0.07
- Stochastic Oscillator
- ASLE 29.33
- ATXS 7.80
About ASLE AerSale Corporation
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.